Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues

M. Vietri, A. Pietrabissa, F. Mosca, R. Spisni, G. M. Pacifici

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

1. Curcumin has anti-carcinogen effects and is under clinical evaluation as a potential colon cancer chemopreventive agent. The first aim was to see whether curcumin inhibited phenol sulfotransferase (SULT1A1) and, if so, to study the variability of the IC50 of curcumin for SULT1A1 in 50 human liver samples. For comparative purposes, the inhibition of catechol sulfotransferase (SULT1A3) in five human liver specimens was studied. The second aim was to measure the IC50 of curcumin against SULT1A1 in five samples of human duodenum, colon, kidney and lung. 2. Curcumin was a potent inhibitor of SULT1A1 in human liver; the mean ± SD and median of IC50 were 14.1 ± 7.3 nM and 12.8 nM, respectively. The IC50 ranged from 6.2 to 30.6 nM between the 5th and 95th percentiles and the fold of variation was 4.9. The distribution of IC50 was positively skewed (skewness 1.2) and deviated from normality (p = 0.0004). 3. Curcumin inhibited human SULT1A3, and the inhibition was studied in five liver specimens with an IC50 of 4324 ± 1026 nM. This inhibition was greater than the IC50 of curcumin for SULT1A1 (p <0.0001). 4. In the extrahepatic tissues, the IC50 of curcumin for SULT1A1 was 25.9 ± 4.8 nM (duodenum), 25.4 ± 6.8 nM (colon), 23.4 ± 2.2 nM (kidney) and 25.6 ± 5.6 nM (lung). Inhibition in these tissues is greater than that of curcumin for SULT1A1 in human liver (p <0.0001). 5. In conclusion, curcumin is a potent inhibitor of SULT1A1 in human liver, duodenum, colon, kidney and lung. The IC50 of curcumin for SULT1A1 varied 4.9-fold in human liver. The comparison of the present data with those of the literature revealed that the IC50 of curcumin in the liver and extrahepatic tissues is one order of magnitude lower that the peak serum concentration of curcumin after therapeutic doses of 4 g to humans.

Original languageEnglish
Pages (from-to)357-363
Number of pages7
JournalXenobiotica
Volume33
Issue number4
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Arylsulfotransferase
Curcumin
Liver
Inhibitory Concentration 50
Tissue
Duodenum
Colon
Kidney
Lung
Sulfotransferases

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Toxicology

Cite this

Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues. / Vietri, M.; Pietrabissa, A.; Mosca, F.; Spisni, R.; Pacifici, G. M.

In: Xenobiotica, Vol. 33, No. 4, 01.04.2003, p. 357-363.

Research output: Contribution to journalArticle

Vietri, M. ; Pietrabissa, A. ; Mosca, F. ; Spisni, R. ; Pacifici, G. M. / Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues. In: Xenobiotica. 2003 ; Vol. 33, No. 4. pp. 357-363.
@article{bbc2700e9583497a958307063298725a,
title = "Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues",
abstract = "1. Curcumin has anti-carcinogen effects and is under clinical evaluation as a potential colon cancer chemopreventive agent. The first aim was to see whether curcumin inhibited phenol sulfotransferase (SULT1A1) and, if so, to study the variability of the IC50 of curcumin for SULT1A1 in 50 human liver samples. For comparative purposes, the inhibition of catechol sulfotransferase (SULT1A3) in five human liver specimens was studied. The second aim was to measure the IC50 of curcumin against SULT1A1 in five samples of human duodenum, colon, kidney and lung. 2. Curcumin was a potent inhibitor of SULT1A1 in human liver; the mean ± SD and median of IC50 were 14.1 ± 7.3 nM and 12.8 nM, respectively. The IC50 ranged from 6.2 to 30.6 nM between the 5th and 95th percentiles and the fold of variation was 4.9. The distribution of IC50 was positively skewed (skewness 1.2) and deviated from normality (p = 0.0004). 3. Curcumin inhibited human SULT1A3, and the inhibition was studied in five liver specimens with an IC50 of 4324 ± 1026 nM. This inhibition was greater than the IC50 of curcumin for SULT1A1 (p <0.0001). 4. In the extrahepatic tissues, the IC50 of curcumin for SULT1A1 was 25.9 ± 4.8 nM (duodenum), 25.4 ± 6.8 nM (colon), 23.4 ± 2.2 nM (kidney) and 25.6 ± 5.6 nM (lung). Inhibition in these tissues is greater than that of curcumin for SULT1A1 in human liver (p <0.0001). 5. In conclusion, curcumin is a potent inhibitor of SULT1A1 in human liver, duodenum, colon, kidney and lung. The IC50 of curcumin for SULT1A1 varied 4.9-fold in human liver. The comparison of the present data with those of the literature revealed that the IC50 of curcumin in the liver and extrahepatic tissues is one order of magnitude lower that the peak serum concentration of curcumin after therapeutic doses of 4 g to humans.",
author = "M. Vietri and A. Pietrabissa and F. Mosca and R. Spisni and Pacifici, {G. M.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1080/0049825031000065197",
language = "English",
volume = "33",
pages = "357--363",
journal = "Xenobiotica",
issn = "0049-8254",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues

AU - Vietri, M.

AU - Pietrabissa, A.

AU - Mosca, F.

AU - Spisni, R.

AU - Pacifici, G. M.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - 1. Curcumin has anti-carcinogen effects and is under clinical evaluation as a potential colon cancer chemopreventive agent. The first aim was to see whether curcumin inhibited phenol sulfotransferase (SULT1A1) and, if so, to study the variability of the IC50 of curcumin for SULT1A1 in 50 human liver samples. For comparative purposes, the inhibition of catechol sulfotransferase (SULT1A3) in five human liver specimens was studied. The second aim was to measure the IC50 of curcumin against SULT1A1 in five samples of human duodenum, colon, kidney and lung. 2. Curcumin was a potent inhibitor of SULT1A1 in human liver; the mean ± SD and median of IC50 were 14.1 ± 7.3 nM and 12.8 nM, respectively. The IC50 ranged from 6.2 to 30.6 nM between the 5th and 95th percentiles and the fold of variation was 4.9. The distribution of IC50 was positively skewed (skewness 1.2) and deviated from normality (p = 0.0004). 3. Curcumin inhibited human SULT1A3, and the inhibition was studied in five liver specimens with an IC50 of 4324 ± 1026 nM. This inhibition was greater than the IC50 of curcumin for SULT1A1 (p <0.0001). 4. In the extrahepatic tissues, the IC50 of curcumin for SULT1A1 was 25.9 ± 4.8 nM (duodenum), 25.4 ± 6.8 nM (colon), 23.4 ± 2.2 nM (kidney) and 25.6 ± 5.6 nM (lung). Inhibition in these tissues is greater than that of curcumin for SULT1A1 in human liver (p <0.0001). 5. In conclusion, curcumin is a potent inhibitor of SULT1A1 in human liver, duodenum, colon, kidney and lung. The IC50 of curcumin for SULT1A1 varied 4.9-fold in human liver. The comparison of the present data with those of the literature revealed that the IC50 of curcumin in the liver and extrahepatic tissues is one order of magnitude lower that the peak serum concentration of curcumin after therapeutic doses of 4 g to humans.

AB - 1. Curcumin has anti-carcinogen effects and is under clinical evaluation as a potential colon cancer chemopreventive agent. The first aim was to see whether curcumin inhibited phenol sulfotransferase (SULT1A1) and, if so, to study the variability of the IC50 of curcumin for SULT1A1 in 50 human liver samples. For comparative purposes, the inhibition of catechol sulfotransferase (SULT1A3) in five human liver specimens was studied. The second aim was to measure the IC50 of curcumin against SULT1A1 in five samples of human duodenum, colon, kidney and lung. 2. Curcumin was a potent inhibitor of SULT1A1 in human liver; the mean ± SD and median of IC50 were 14.1 ± 7.3 nM and 12.8 nM, respectively. The IC50 ranged from 6.2 to 30.6 nM between the 5th and 95th percentiles and the fold of variation was 4.9. The distribution of IC50 was positively skewed (skewness 1.2) and deviated from normality (p = 0.0004). 3. Curcumin inhibited human SULT1A3, and the inhibition was studied in five liver specimens with an IC50 of 4324 ± 1026 nM. This inhibition was greater than the IC50 of curcumin for SULT1A1 (p <0.0001). 4. In the extrahepatic tissues, the IC50 of curcumin for SULT1A1 was 25.9 ± 4.8 nM (duodenum), 25.4 ± 6.8 nM (colon), 23.4 ± 2.2 nM (kidney) and 25.6 ± 5.6 nM (lung). Inhibition in these tissues is greater than that of curcumin for SULT1A1 in human liver (p <0.0001). 5. In conclusion, curcumin is a potent inhibitor of SULT1A1 in human liver, duodenum, colon, kidney and lung. The IC50 of curcumin for SULT1A1 varied 4.9-fold in human liver. The comparison of the present data with those of the literature revealed that the IC50 of curcumin in the liver and extrahepatic tissues is one order of magnitude lower that the peak serum concentration of curcumin after therapeutic doses of 4 g to humans.

UR - http://www.scopus.com/inward/record.url?scp=0038509950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038509950&partnerID=8YFLogxK

U2 - 10.1080/0049825031000065197

DO - 10.1080/0049825031000065197

M3 - Article

C2 - 12745871

AN - SCOPUS:0038509950

VL - 33

SP - 357

EP - 363

JO - Xenobiotica

JF - Xenobiotica

SN - 0049-8254

IS - 4

ER -